Nykode Therapeutics AS (OSL:NYKD)

kr 2.974 -0.046 (-1.52%) Market Cap: 971.15 Mil Enterprise Value: -397.26 Mil PE Ratio: 0 PB Ratio: 0.65 GF Score: 46/100

Q3 2024 Nykode Therapeutics ASA Earnings Call Transcript
Nov 27, 2024

kr2.83 (+5.05%)

Earnings
Q2 2024 Nykode Therapeutics ASA Earnings Call Transcript
Aug 21, 2024

kr5.56 (-47.04%)

Earnings
Q1 2024 Nykode Therapeutics ASA Earnings Call Transcript
May 14, 2024

kr14.35 (+2.14%)

Earnings
Q4 2023 Nykode Therapeutics ASA Earnings Call Transcript
Feb 28, 2024

kr16.94 (-5.84%)

Earnings
Q2 2023 Nykode Therapeutics ASA Earnings Call Transcript
Aug 23, 2023

kr26.58 (-0.23%)

Earnings
Nykode Therapeutics ASA at Jefferies Healthcare Conference Transcript
Jun 07, 2023
Q1 2023 Nykode Therapeutics ASA Earnings Call Transcript
May 12, 2023

kr26.78 (+5.68%)

Earnings
Q4 2022 Nykode Therapeutics ASA Earnings Call Transcript
Feb 28, 2023

kr26.42 (-2.51%)

Earnings
Nykode Therapeutics ASA Corporate Call Transcript
Dec 20, 2022
Q3 2022 Nykode Therapeutics ASA Earnings Call Transcript
Nov 23, 2022

kr25.18 (-1.79%)

Earnings
Nykode Therapeutics ASA at Jefferies London Healthcare Conference Transcript
Nov 17, 2022
Nykode Therapeutics AS at Jefferies Healthcare Conference Transcript
Jun 08, 2022
Vaccibody AS Call to Discuss License Agreement with Adaptive Biotechnologies Corp Transcript
Jul 12, 2021

Q4 2023 Nykode Therapeutics ASA Earnings Call Transcript

Feb 28, 2024 / 03:00PM GMT

Release Date Price: kr16.94 (-5.84%)

Transcript

Operator

Greetings, and welcome to Nykode Therapeutics Q4 2023 financial results presentation. (Operator Instructions) As a reminder, this conference is being recorded.

I would now like to turn the conference over to your host, Michael Engsig, CEO of Nykode. Please go ahead.

Michael Engsig

Nykode Therapeutics ASA - CEO

Thank you very much and to all our participants, a very warm welcome to the Q4 webcast from Micro Therapeutics, and we assume you're all familiar with the forward-looking statements of my code. And on that note, I will move on.

It's my pleasure today to be joined at this, what we call here by my colleagues, Agnete Fredriksen, Chief Business Officer and Co-Founder; Harald Gurvin, our Chief Financial Officer; as well as Klaus Edvardsen, our Chief Development Officer, who will help me guide you through the highlights of the fourth quarter and answer any questions that you may submit in the system.

So Q4 was another very exciting quarter for us with a good, solid progress for the Company, and we expanded the oncology pipeline

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.